Literature DB >> 10194829

Measles vaccines, new developments and immunization strategies.

T F Wild1.   

Abstract

The development of an attenuated measles virus vaccine gave us a tool to combat a disease which has ravaged the child population throughout the centuries. Three decades later the vaccine has shown its qualities and its problems. Using this vaccine the WHO have decided on a measles eradication policy. This article discusses some of the issues which are being addressed and possible solutions.

Entities:  

Mesh:

Substances:

Year:  1999        PMID: 10194829     DOI: 10.1016/s0264-410x(98)00428-9

Source DB:  PubMed          Journal:  Vaccine        ISSN: 0264-410X            Impact factor:   3.641


  5 in total

1.  The use of oral fluid samples spotted on filter paper for the detection of measles virus using nested rt-PCR.

Authors:  Sogol Sheikhakbari; Talat Mokhtari-Azad; Vahid Salimi; Zahra Norouzbabaei; Simin Abbasi; Seyed Mohsen Zahraei; Shohreh Shahmahmoodi
Journal:  J Clin Lab Anal       Date:  2012-05       Impact factor: 2.352

2.  Neutralizing human Fab fragments against measles virus recovered by phage display.

Authors:  Cristina de Carvalho Nicacio; R Anthony Williamson; Paul W H I Parren; Ake Lundkvist; Dennis R Burton; Ewa Björling
Journal:  J Virol       Date:  2002-01       Impact factor: 5.103

3.  Combination of reverse transcriptase PCR analysis and immunoglobulin M detection on filter paper blood samples allows diagnostic and epidemiological studies of measles.

Authors:  R L De Swart; Y Nur; A Abdallah; H Kruining; H S El Mubarak; S A Ibrahim; B Van Den Hoogen; J Groen; A D Osterhaus
Journal:  J Clin Microbiol       Date:  2001-01       Impact factor: 5.948

4.  Protective immunity in macaques vaccinated with a modified vaccinia virus Ankara-based measles virus vaccine in the presence of passively acquired antibodies.

Authors:  K J Stittelaar; L S Wyatt; R L de Swart; H W Vos; J Groen; G van Amerongen; R S van Binnendijk; S Rozenblatt; B Moss; A D Osterhaus
Journal:  J Virol       Date:  2000-05       Impact factor: 5.103

Review 5.  Neutralizing antiviral antibody responses.

Authors:  R M Zinkernagel; A LaMarre; A Ciurea; L Hunziker; A F Ochsenbein; K D McCoy; T Fehr; M F Bachmann; U Kalinke; H Hengartner
Journal:  Adv Immunol       Date:  2001       Impact factor: 3.543

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.